|
The Immunohistochemistry Antibody Company
|
- Home
-
Products
- All Antibodies
- IHC-plus Antibodies
-
Services
- Immunohistochemistry Studies
- Tissue Cross-Reactivity Screening
- Distributors
-
Resources
- About our Tissue Bank
- Customer Support
- How to Buy
- IHC-plus Protocol
- LSBio Media
- Publications
- Antibody Reports
-
Company
- About LifeSpan
- Press Releases
- Holiday Schedule
- Contact Us
|
|
Lung Cancer Screen 31 Tissue Microarray - LS-SLUCA31
This tissue microarray is available for use in LSBio Immunohistochemistry Studies only.
|
|
| Catalog ID: |
LS-SLUCA31 |
| Product Name: |
Lung Cancer Screen 31 |
| Description: |
Lung cancer |
| Format: |
FFPE |
| Category: |
Human Tumor |
| QA/QC: |
H&E reviewed; IHC validated with a positive control antibody |
| Storage: |
Short term RT; Long term 4ºC |
| Clinical History: |
No |
| Tissue Marker: |
No |
| Stage/Grade: |
Yes |
| Core Diameter: |
1.1 mm |
| Core Thickness: |
4 µm |
| Cases: |
75 |
| Cores: |
150 |
| Slides Per Set: |
1 |
LS-SLUCA31 Tissue Microarray Map
Slide Number 1
| LABEL | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | | A | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | B | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | C | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | D | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | E | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | F | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | G | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | H | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | I | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | | J | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng | Lng |
|
Diagnosis Type Legend| Benign non-neoplastic | Diseased | Inflammatory | Malignant | Metastatic | Tumor | Unknown |
Element Tissue LegendLung (Lng);
LS-SLUCA31 Element Details
| Slide | Position | Species | Gender | Age | Tissue | Diagnosis | Diagnosis Type | TNM Tumor Classification | Tumor Grade | Tumor Differentiation |
|---|
| 1 | A1 | Human | M | 19 y | Lung (Lng) | Normal | Benign non-neoplastic | | | |
| 1 | A2 | Human | F | 35 y | Lung (Lng) | Normal | Benign non-neoplastic | | | |
| 1 | A3 | Human | M | 61 y | Lung (Lng) | Inflammation | Inflammatory | | | |
| 1 | A4 | Human | M | 56 y | Lung (Lng) | Chronic bronchitis | Inflammatory | | | |
| 1 | A5 | Human | M | 56 y | Lung (Lng) | Tuberculosis | Diseased | | | |
| 1 | A6 | Human | M | 57 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | A7 | Human | F | 46 y | Lung (Lng) | Papillary carcinoma | Malignant | T3N1M0 | Grade II-III | |
| 1 | A8 | Human | M | 66 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | A9 | Human | M | 62 y | Lung (Lng) | Small cell carcinoma | Malignant | T2N0M0 | | |
| 1 | A10 | Human | M | 50 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade III | |
| 1 | A11 | Human | M | 58 y | Lung (Lng) | Small cell carcinoma | Malignant | T2N1M0 | Grade III | |
| 1 | A12 | Human | M | 50 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | A13 | Human | F | 19 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | A14 | Human | M | 73 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T1N0M0 | Grade III | |
| 1 | A15 | Human | M | 39 y | Lung (Lng) | Small cell carcinoma | Malignant | T2N0M0 | | |
| 1 | B1 | Human | M | 19 y | Lung (Lng) | Normal | Benign non-neoplastic | | | |
| 1 | B2 | Human | F | 35 y | Lung (Lng) | Normal | Benign non-neoplastic | | | |
| 1 | B3 | Human | M | 61 y | Lung (Lng) | Inflammation | Inflammatory | | | |
| 1 | B4 | Human | M | 56 y | Lung (Lng) | Chronic bronchitis | Inflammatory | | | |
| 1 | B5 | Human | M | 56 y | Lung (Lng) | Tuberculosis | Diseased | | | |
| 1 | B6 | Human | M | 57 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | B7 | Human | F | 46 y | Lung (Lng) | Papillary carcinoma | Malignant | T3N1M0 | Grade II-III | |
| 1 | B8 | Human | M | 66 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | B9 | Human | M | 62 y | Lung (Lng) | Small cell carcinoma | Malignant | T2N0M0 | | |
| 1 | B10 | Human | M | 50 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade III | |
| 1 | B11 | Human | M | 58 y | Lung (Lng) | Small cell carcinoma | Malignant | T2N1M0 | Grade III | |
| 1 | B12 | Human | M | 50 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | B13 | Human | F | 19 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | B14 | Human | M | 73 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T1N0M0 | Grade III | |
| 1 | B15 | Human | M | 39 y | Lung (Lng) | Small cell carcinoma | Malignant | T2N0M0 | | |
| 1 | C1 | Human | F | 60 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade III | |
| 1 | C2 | Human | M | 49 y | Lung (Lng) | Adenosquamous carcinoma | Malignant | T1N0M0 | | |
| 1 | C3 | Human | F | 21 y | Lung (Lng) | Sarcoma | Malignant | | | |
| 1 | C4 | Human | F | 50 y | Lung (Lng) | Mesothelioma | Tumor | | | |
| 1 | C5 | Human | M | 74 y | Lung (Lng) | Adenosquamous carcinoma | Malignant | T1N0M0 | | |
| 1 | C6 | Human | M | 63 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | C7 | Human | M | 48 y | Lung (Lng) | Carcinoma | Malignant | T2N0M0 | | Undifferentiated |
| 1 | C8 | Human | F | 62 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | C9 | Human | M | 62 y | Lung (Lng) | Neuronendocrine carcinoma | Malignant | T2N0M0 | | |
| 1 | C10 | Human | M | 60 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | C11 | Human | M | 65 y | Lung (Lng) | Sarcoma | Malignant | | | |
| 1 | C12 | Human | F | 64 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | C13 | Human | M | 58 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | C14 | Human | M | 70 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade I-II | |
| 1 | C15 | Human | F | 67 y | Lung (Lng) | Adenosquamous carcinoma | Malignant | T2N1M0 | | |
| 1 | D1 | Human | F | 60 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade III | |
| 1 | D2 | Human | M | 49 y | Lung (Lng) | Adenosquamous carcinoma | Malignant | T1N0M0 | | |
| 1 | D3 | Human | F | 21 y | Lung (Lng) | Sarcoma | Malignant | | | |
| 1 | D4 | Human | F | 50 y | Lung (Lng) | Mesothelioma | Tumor | | | |
| 1 | D5 | Human | M | 74 y | Lung (Lng) | Adenosquamous carcinoma | Malignant | T1N0M0 | | |
| 1 | D6 | Human | M | 63 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | D7 | Human | M | 48 y | Lung (Lng) | Carcinoma | Malignant | T2N0M0 | | Undifferentiated |
| 1 | D8 | Human | F | 62 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | D9 | Human | M | 62 y | Lung (Lng) | Neuronendocrine carcinoma | Malignant | T2N0M0 | | |
| 1 | D10 | Human | M | 60 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | D11 | Human | M | 65 y | Lung (Lng) | Sarcoma | Malignant | | | |
| 1 | D12 | Human | F | 64 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | D13 | Human | M | 58 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | D14 | Human | M | 70 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade I-II | |
| 1 | D15 | Human | F | 67 y | Lung (Lng) | Adenosquamous carcinoma | Malignant | T2N1M0 | | |
| 1 | E1 | Human | M | 62 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T1N0M0 | Grade III | |
| 1 | E2 | Human | M | 53 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | E3 | Human | M | 54 y | Lung (Lng) | Mesothelioma | Tumor | T2N1M0 | | |
| 1 | E4 | Human | M | 66 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T1N0M0 | | |
| 1 | E5 | Human | M | 69 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | E6 | Human | M | 60 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | E7 | Human | M | 51 y | Lung (Lng) | Small cell carcinoma | Malignant | T2N2M0 | | |
| 1 | E8 | Human | M | 69 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade I | |
| 1 | E9 | Human | M | 45 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | E10 | Human | M | 69 y | Lung (Lng) | Large cell carcinoma | Malignant | T2N0M0 | | Undifferentiated |
| 1 | E11 | Human | M | 70 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade II-III | |
| 1 | E12 | Human | M | 60 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | E13 | Human | M | 50 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | E14 | Human | M | 49 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | E15 | Human | M | 20 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade II-III | |
| 1 | F1 | Human | M | 62 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T1N0M0 | Grade III | |
| 1 | F2 | Human | M | 53 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | F3 | Human | M | 54 y | Lung (Lng) | Mesothelioma | Tumor | T2N1M0 | | |
| 1 | F4 | Human | M | 66 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T1N0M0 | | |
| 1 | F5 | Human | M | 69 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | F6 | Human | M | 60 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | F7 | Human | M | 51 y | Lung (Lng) | Small cell carcinoma | Malignant | T2N2M0 | | |
| 1 | F8 | Human | M | 69 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade I | |
| 1 | F9 | Human | M | 45 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | F10 | Human | M | 69 y | Lung (Lng) | Large cell carcinoma | Malignant | T2N0M0 | | Undifferentiated |
| 1 | F11 | Human | M | 70 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade II-III | |
| 1 | F12 | Human | M | 60 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | F13 | Human | M | 50 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | F14 | Human | M | 49 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | F15 | Human | M | 20 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade II-III | |
| 1 | G1 | Human | M | 78 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | G2 | Human | M | 56 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | G3 | Human | M | 65 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | G4 | Human | M | 57 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T2N0M0 | | |
| 1 | G5 | Human | M | 66 y | Lung (Lng) | Neuronendocrine carcinoma | Malignant | | | |
| 1 | G6 | Human | M | 52 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | G7 | Human | F | 51 y | Lung (Lng) | Large cell carcinoma | Malignant | T2N1M0 | | Undifferentiated |
| 1 | G8 | Human | M | 42 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T2N1M0 | | |
| 1 | G9 | Human | F | 44 y | Lung (Lng) | Neuronendocrine carcinoma | Malignant | | | |
| 1 | G10 | Human | F | 48 y | Lung (Lng) | Carcinoma | Malignant | T2N0M0 | | Undifferentiated |
| 1 | G11 | Human | M | 42 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T2N0M0 | | |
| 1 | G12 | Human | F | 43 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | G13 | Human | M | 66 y | Lung (Lng) | Squamous cell carcinoma | Malignant | | Grade III | |
| 1 | G14 | Human | M | 50 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade II | |
| 1 | G15 | Human | M | 54 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | H1 | Human | M | 78 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | H2 | Human | M | 56 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | H3 | Human | M | 65 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | H4 | Human | M | 57 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T2N0M0 | | |
| 1 | H5 | Human | M | 66 y | Lung (Lng) | Neuronendocrine carcinoma | Malignant | | | |
| 1 | H6 | Human | M | 52 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | H7 | Human | F | 51 y | Lung (Lng) | Large cell carcinoma | Malignant | T2N1M0 | | Undifferentiated |
| 1 | H8 | Human | M | 42 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T2N1M0 | | |
| 1 | H9 | Human | F | 44 y | Lung (Lng) | Neuronendocrine carcinoma | Malignant | | | |
| 1 | H10 | Human | F | 48 y | Lung (Lng) | Carcinoma | Malignant | T2N0M0 | | Undifferentiated |
| 1 | H11 | Human | M | 42 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T2N0M0 | | |
| 1 | H12 | Human | F | 43 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | H13 | Human | M | 66 y | Lung (Lng) | Squamous cell carcinoma | Malignant | | Grade III | |
| 1 | H14 | Human | M | 50 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade II | |
| 1 | H15 | Human | M | 54 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | I1 | Human | M | 60 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T2N1M0 | | |
| 1 | I2 | Human | M | 11 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | I3 | Human | M | 76 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade II | |
| 1 | I4 | Human | M | 77 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade III | |
| 1 | I5 | Human | F | 51 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | I6 | Human | M | 46 y | Lung (Lng) | Mucinous adenocarcinoma | Malignant | T2N0M0 | | |
| 1 | I7 | Human | M | 56 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade I | |
| 1 | I8 | Human | M | 52 y | Lung (Lng) | Adenosquamous carcinoma | Malignant | T2N0M0 | | |
| 1 | I9 | Human | M | 74 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | I10 | Human | M | 70 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | I11 | Human | M | 51 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | I12 | Human | M | 55 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | I13 | Human | M | 62 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade I | |
| 1 | I14 | Human | M | 58 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | I15 | Human | M | 50 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | J1 | Human | M | 60 y | Lung (Lng) | Bronchioloalveolar carcinoma | Malignant | T2N1M0 | | |
| 1 | J2 | Human | M | 11 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | J3 | Human | M | 76 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade II | |
| 1 | J4 | Human | M | 77 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade III | |
| 1 | J5 | Human | F | 51 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | J6 | Human | M | 46 y | Lung (Lng) | Mucinous adenocarcinoma | Malignant | T2N0M0 | | |
| 1 | J7 | Human | M | 56 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N1M0 | Grade I | |
| 1 | J8 | Human | M | 52 y | Lung (Lng) | Adenosquamous carcinoma | Malignant | T2N0M0 | | |
| 1 | J9 | Human | M | 74 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | J10 | Human | M | 70 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | J11 | Human | M | 51 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
| 1 | J12 | Human | M | 55 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II | |
| 1 | J13 | Human | M | 62 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade I | |
| 1 | J14 | Human | M | 58 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III | |
| 1 | J15 | Human | M | 50 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade III | |
Copyright © 2013 LifeSpan BioSciences, Inc. All Rights Reserved
